Literature DB >> 17368289

Surgical treatment of pancreatic endocrine neoplasms.

Fernando Gomez-Rivera1, Ashley E Stewart, J Pablo Arnoletti, Selwyn Vickers, Kirby I Bland, Martin J Heslin.   

Abstract

BACKGROUND: Pancreatic endocrine neoplasia (PEN) is an entity with an indolent course and prolonged survival. The aim of the current study was to review the prognostic factors and outcome of patients with PEN at 1 institution.
METHODS: Records of patients with the diagnosis of PEN in the period of 1980 to 2001 were reviewed. Descriptive statistics and log-rank test were used; significance was defined as P < .05.
RESULTS: Of 49 patients, 25 had functional and 24 nonfunctional tumors. Surgery was performed in 43 patients, 36 with curative intent. With a median follow-up of 31 months, there were 5 deaths. Symptoms were controlled with surgical resection in 86%. Median disease-free survival (DFS) was 46 months; actuarial 5-year disease-specific (DSS) was 72%. Factors associated with better DFS and DSS were absence of liver involvement (P = .02) and resection of the primary tumor (P = .04).
CONCLUSIONS: Surgical resection and absence of liver metastases are associated with better DFS and DSS in patients with PEN.

Entities:  

Mesh:

Year:  2007        PMID: 17368289     DOI: 10.1016/j.amjsurg.2006.10.016

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Breast and lung metastasis from pancreatic neuroendocrine carcinoma.

Authors:  Shevonne Satahoo-Dawes; Joshua Palmer; Eddie W Manning; Joe Levi
Journal:  World J Radiol       Date:  2011-01-28

Review 2.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

3.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

4.  Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.

Authors:  Paul A Toste; Brian E Kadera; Sergei F Tatishchev; David W Dawson; Barbara M Clerkin; Raman Muthusamy; Rabindra Watson; James S Tomlinson; Oscar J Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2013-10-08       Impact factor: 3.452

Review 5.  Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas.

Authors:  Ian W Folkert; Paul Hernandez; Robert E Roses
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

Review 6.  Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.

Authors:  Sven-Petter Haugvik; Knut Jørgen Labori; Bjørn Edwin; Øystein Mathisen; Ivar Prydz Gladhaug
Journal:  ScientificWorldJournal       Date:  2012-12-10

7.  Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors.

Authors:  Yu Jiang; Jia-Bin Jin; Qian Zhan; Xia-Xing Deng; Bai-Yong Shen
Journal:  Chin Med J (Engl)       Date:  2015-12-20       Impact factor: 2.628

8.  The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours.

Authors:  Daniel J Cuthbertson; Jorge Barriuso; Angela Lamarca; Prakash Manoharan; Thomas Westwood; Matthew Jaffa; Stephen W Fenwick; Christina Nuttall; Fiona Lalloo; Andreas Prachalias; Michail Pizanias; Hulya Wieshmann; Mairead G McNamara; Richard Hubner; Raj Srirajaskanthan; Gillian Vivian; John Ramage; Martin O Weickert; D Mark Pritchard; Sobhan Vinjamuri; Juan Valle; Vincent S Yip
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-07       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.